Subscribe To
Sellas receives fda orphan drug designation for sls009 for treatment of acute myeloid leukemia
NEW YORK, Oct. 10, 2023 (GLOBE NEWSWIRE) — SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clini...
October 10, 2023, 8:15 pm
Illumina to get eu order on thursday to divest grail, source says
U.S. genetic testing company Illumina will on Thursday get an order from EU antitrust regulators to sell cance...
October 10, 2023, 6:14 pm
Rayzebio: initiating coverage with buy rating and a price target of $43
Initiating RayzeBio, Inc. coverage with a Buy rating and common stock price target of $43 based on my risk-adjusted NPV discounted cash flow model, re...
October 10, 2023, 2:10 pm
cancer biotechs pique buyout interest: recent deals in focus
The M&A trend of 2023 shows that there is an increasing interest in biotech companies making innovative cancer...
October 10, 2023, 12:47 pm
Cybrexa therapeutics to debut preclinical data demonstrating cbx-15 is safe and highly efficacious in 13762 triple negative breast cancer model at 35th aacr-nci-eortc symposium
Preclinical Data Demonstrate CBX-15’s Anti-Tumor Efficacy in Animal Models and Ability to Enhance Immunogenicity and Induce Immune Memory through pH...
October 10, 2023, 12:05 pm
Bioatla provides guidance on near-term milestones and plans to announce third quarter 2023 financial results and business update on november 7, 2023
Submitted abstract on CAB-AXL-ADC, BA3011, in non-small cell lung cancer (NSCLC) to the IASLC 2023 Nort...
October 10, 2023, 11:30 am
Merck immunotherapy shows further promise in lung cancer
Merck & Co confirmed that its cancer drug Keytruda has successfully met the second of its two primary ...
October 10, 2023, 9:11 am
Why is nucana (ncna) stock down today?
NuCana (NASDAQ: NCNA ) stock is sliding lower on Tuesday as the clinical-stage biopharmaceutical company prepares for a presentation this week. NuCan...
October 10, 2023, 8:46 am
Merck reports positive results for blockbuster cancer drug in treating non-small cell lung cancer
Merck & Co. said Tuesday a late-stage trial of its blockbuster cancer drug Keytruda as a treatment for ...
October 10, 2023, 6:56 am
A bull market is coming: 1 beaten-down growth stock you could regret not buying on the dip
Caribou Biosciences stock could rocket up more than 400%, according to the consensus price target from Wall Street analysts. Caribou's lead candidate ...
October 10, 2023, 5:40 am
Bristol-myers squibb to acquire mirati in up to $5.8 billion deal
CNBC's Angelica Peebles joins 'Closing Bell: Overtime' to discuss Bristol-Myers Squibb on Sunday said it will acquire ...
October 9, 2023, 5:16 pm
Harpoon therapeutics to present interim tolerability and response data from phase 1/2 clinical trial of t cell engager hpn328 at esmo congress 2023
SOUTH SAN FRANCISCO, Calif., Oct. 09, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company deve...
October 9, 2023, 4:17 pm
Kineta to present preclinical data on vista blocking kva12123 at immuno us 2023
SEATTLE, Oct. 09, 2023 (GLOBE NEWSWIRE) — Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immu...
October 9, 2023, 4:10 pm
Kineta to present preclinical data on vista blocking kva12123 at immuno us 2023
SEATTLE, Oct. 09, 2023 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immun...
October 9, 2023, 12:10 pm
Bristol-myers squibb buys mirati therapeutics to boost cancer drug portfolio
Bristol-Myers Squibb (BMY) moved to expand its reach into cancer-fighting drugs by buying Mirati Therap...
October 9, 2023, 12:05 pm
Bristol myers (bmy) to acquire mirati therapeutics for $5.8 b
Bristol Myers (BMY) to offset its declining revenues from top drugs with the acquisition of Mirati Therapeutics, which will add lung ...
October 9, 2023, 12:02 pm
Why shares of tango therapeutics are dropping monday
Tango Therapeutics is a clinical-stage biotech. The company has five programs in its pipeline that are focused on fighting various ...
October 9, 2023, 11:53 am
Bristol myers squibb to buy cancer drugmaker mirati therapeutics in up to $5.8b deal
Bristol Myers Squibb will buy Mirati Therapeutics in a deal worth up to $5.8 billion, or $58 per share, the biopharmaceutical company announced Sunday...
October 9, 2023, 11:40 am
Plus therapeutics to participate in the jones trading healthcare summit and thinkequity conference in october
AUSTIN, Texas, Oct. 09, 2023 (GLOBE NEWSWIRE) — Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company ...
October 9, 2023, 11:00 am
Bristol-myers squibb to acquire mirati in deal worth up to $5.8b
Bristol-Myers Squibb (BMY) agreed to buy cancer drugmaker Mirati Therapeutics (MRTX) for up to $5.8 bil...
October 9, 2023, 10:48 am